AJR F and L Medical Products: Radiation Protection & More
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nishino, M.
Right arrow Articles by Mukaihara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nishino, M.
Right arrow Articles by Mukaihara, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
AJR 2003; 180:129-134
© American Roentgen Ray Society

Effects of Tamoxifen on Hepatic Fat Content and the Development of Hepatic Steatosis in Patients with Breast Cancer: High Frequency of Involvement and Rapid Reversal After Completion of Tamoxifen Therapy

Mizuki Nishino1, Katsumi Hayakawa1, Yoshiaki Nakamura2, Taisuke Morimoto2 and Sumio Mukaihara2

1 Department of Radiology, Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyo-ku, Kyoto 604-8845, Japan.
2 Department of Surgery, Kyoto City Hospital, Kyoto 604-8845, Japan.

OBJECTIVE. A study was conducted on hepatic fat content to investigate the frequency and clinical course of hepatic steatosis induced by tamoxifen.

MATERIALS AND METHODS. Sixty-seven patients with breast cancer treated with adjuvant tamoxifen were included. The patients underwent postoperative annual abdominal CT, both with and without contrast enhancement, for 5 years. We retrospectively reviewed unenhanced CT images and obtained hepatic and splenic CT attenuation values to calculate the liver—spleen ratio. Hepatic steatosis was defined as a liver—spleen ratio of less than 0:9, and its degree was classified as mild (liver—spleen ratio, 0:5-0:9), moderate (0-0:5), or severe (<0). The pattern of steatosis was classified as generalized, lobar, segmental, or focal.

RESULTS. In the study population, hepatic CT values decreased during therapy (p < 0.0001, t test) and increased after therapy (p < 0.0001, paired t test). Twenty-nine patients (43.2%) developed hepatic steatosis within the first 2 years; its degree was mild in 16, moderate in nine, and severe in four. Seventeen patients showed a generalized pattern of steatosis, and the other 12 showed a lobar pattern. Twenty-three of these patients showed an increase in the liver—spleen ratio after therapy to within the normal range, with a mean recovery time of 1.2 years after therapy ended. None progressed to steatohepatitis or cirrhosis.

CONCLUSION. Tamoxifen had a statistically significant influence on hepatic fat content and was associated with frequent development of hepatic steatosis. Radiologists should be aware of this phenomenon and the possible occurrence of hepatic dysfunction and should differentiate steatosis from metastasis in postoperative patients with breast cancer.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
C. Denzer, D. Thiere, R. Muche, W. Koenig, H. Mayer, W. Kratzer, and M. Wabitsch
Gender-Specific Prevalences of Fatty Liver in Obese Children and Adolescents: Roles of Body Fat Distribution, Sex Steroids, and Insulin Resistance
J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3872 - 3881.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri
Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M Brookes, D MacVicar, and J Husband
Metastatic carcinoma of the breast: the appearances of metastatic spread to the abdomen and pelvis as demonstrated by CT
Br. J. Radiol., April 1, 2007; 80(952): 284 - 292.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
O. A. Gudbrandsen, T. H. Rost, and R. K. Berge
Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver
J. Lipid Res., October 1, 2006; 47(10): 2223 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. J. Lelliott, M. Lopez, R. K. Curtis, N. Parker, M. Laudes, G. Yeo, M. Jimenez-Linan, J. Grosse, A. K. Saha, D. Wiggins, et al.
Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis
FASEB J, July 1, 2005; 19(9): 1108 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
S. Bruno, P. Maisonneuve, P. Castellana, N. Rotmensz, S. Rossi, M. Maggioni, M. Persico, A. Colombo, F. Monasterolo, D. Casadei-Giunchi, et al.
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
BMJ, April 23, 2005; 330(7497): 932.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Roentgen Ray Society.